JP7068185B2 - 縮合四環式の化合物、組成物及びその使用 - Google Patents

縮合四環式の化合物、組成物及びその使用 Download PDF

Info

Publication number
JP7068185B2
JP7068185B2 JP2018553855A JP2018553855A JP7068185B2 JP 7068185 B2 JP7068185 B2 JP 7068185B2 JP 2018553855 A JP2018553855 A JP 2018553855A JP 2018553855 A JP2018553855 A JP 2018553855A JP 7068185 B2 JP7068185 B2 JP 7068185B2
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
diazepine
mmol
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501971A (ja
JP2019501971A5 (enExample
Inventor
マッコマス，キャシー，キャメロン
セラノ－ウー，マイケル，エイチ．
ヴァッカ，ジョセフ，ピー．
Original Assignee
タボメデックス バイオサイエンシズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タボメデックス バイオサイエンシズ インコーポレーテッド filed Critical タボメデックス バイオサイエンシズ インコーポレーテッド
Publication of JP2019501971A publication Critical patent/JP2019501971A/ja
Publication of JP2019501971A5 publication Critical patent/JP2019501971A5/ja
Application granted granted Critical
Publication of JP7068185B2 publication Critical patent/JP7068185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018553855A 2016-01-04 2017-01-04 縮合四環式の化合物、組成物及びその使用 Active JP7068185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662274640P 2016-01-04 2016-01-04
US62/274,640 2016-01-04
PCT/US2017/012092 WO2017120164A1 (en) 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2019501971A JP2019501971A (ja) 2019-01-24
JP2019501971A5 JP2019501971A5 (enExample) 2020-02-13
JP7068185B2 true JP7068185B2 (ja) 2022-05-16

Family

ID=59226993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553855A Active JP7068185B2 (ja) 2016-01-04 2017-01-04 縮合四環式の化合物、組成物及びその使用

Country Status (9)

Country Link
US (2) US10059718B2 (enExample)
EP (1) EP3400228B1 (enExample)
JP (1) JP7068185B2 (enExample)
CN (1) CN108779123B (enExample)
AU (1) AU2017205320B2 (enExample)
CA (1) CA3010213A1 (enExample)
ES (1) ES2915901T3 (enExample)
TW (1) TWI730027B (enExample)
WO (1) WO2017120164A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
WO2022150707A1 (en) * 2021-01-11 2022-07-14 Tabomedex Biosciences, Inc. Fused quadracyclic compounds, compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517070A (ja) 2000-11-16 2004-06-10 エフ．ホフマン−ラ　ロシュ　アーゲー Ｇａｂａａ受容体モデュレーターとしてのベンゾジアゼピン誘導体
JP2006511583A (ja) 2002-12-20 2006-04-06 ファルマシア・コーポレーション マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２を阻害するための非環式ピラゾール化合物
WO2014149164A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use
US4596799A (en) 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
US20160066387A1 (en) * 2013-03-22 2016-03-03 Lifi Labs Inc Color selection
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517070A (ja) 2000-11-16 2004-06-10 エフ．ホフマン−ラ　ロシュ　アーゲー Ｇａｂａａ受容体モデュレーターとしてのベンゾジアゼピン誘導体
JP2006511583A (ja) 2002-12-20 2006-04-06 ファルマシア・コーポレーション マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２を阻害するための非環式ピラゾール化合物
WO2014149164A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rao, Ashwin U., Xiao, Dong et al，"Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors"，Bioorganic & Medicinal Chemistry Letters，2012年，Vol.22(2)，p.1068-1072

Also Published As

Publication number Publication date
EP3400228A4 (en) 2019-08-14
AU2017205320A1 (en) 2018-07-05
EP3400228B1 (en) 2022-04-13
TW201726681A (zh) 2017-08-01
JP2019501971A (ja) 2019-01-24
CA3010213A1 (en) 2017-07-13
AU2017205320B2 (en) 2021-06-24
US10562909B2 (en) 2020-02-18
WO2017120164A1 (en) 2017-07-13
US20170190713A1 (en) 2017-07-06
ES2915901T3 (es) 2022-06-27
US20180319809A1 (en) 2018-11-08
TWI730027B (zh) 2021-06-11
US10059718B2 (en) 2018-08-28
CN108779123B (zh) 2025-08-19
EP3400228A1 (en) 2018-11-14
CN108779123A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
TWI626050B (zh) 吡唑並［１，５-ａ］嘧啶類之醫藥組成物與用途
CN110167560A (zh) 四环素化合物和治疗方法
EP3538526A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
JP2024505261A (ja) Ｃｄｋ２阻害剤およびその使用方法
WO2022194269A1 (zh) 新型egfr降解剂
CN120712271A (zh) 作为kras g12d抑制剂的新型三环化合物及其用途
AU2018334272A1 (en) Tetrahydro-imidazo quinoline compositions as CBP/p300 inhibitors
JP2021500380A (ja) Ｐ２ｘ３阻害剤としての新規なピラゾロ−ピロロ−ピリミジン−ジオン誘導体
JP7068185B2 (ja) 縮合四環式の化合物、組成物及びその使用
TW202448452A (zh) 用於治療疾病之ｅｇｆｒ抑制劑
KR20230157467A (ko) 모세혈관 확장성 운동실조증 돌연변이(atm) 키나아제의 선택적 조절제 및 이의 용도
HK40006173A (en) Fused quadracyclic compounds, compositions and uses thereof
JP2023509496A (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
JP2025540246A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤として新規な３環化合物およびその用途
CN119894908A (zh) Egfr抑制剂和其用途
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK1254323A1 (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20201214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220428

R150 Certificate of patent or registration of utility model

Ref document number: 7068185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250